Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome

NCT03882918 is registered in ClinicalTrials.gov with Healx AI as lead sponsor.

NCT NCT03882918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03882918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
Lead sponsor
Healx AI
Phase
Phase 3
Overall status
Terminated
Start date
January 31, 2019
Completion date
June 30, 2021
Enrollment
141 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

angelman syndrome